Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants
Abstract Background Breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are well documented. The current study estimates breakthrough incidence across pandemic waves, and evaluates predictors of breakthrough and severe breakthrough infections (defined as those req...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2023-05, Vol.227 (10), p.1164-1172 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1172 |
|---|---|
| container_issue | 10 |
| container_start_page | 1164 |
| container_title | The Journal of infectious diseases |
| container_volume | 227 |
| creator | DeSantis, Stacia M Yaseen, Ashraf Hao, Tianyao León-Novelo, Luis Talebi, Yashar Valerio-Shewmaker, Melissa A Pinzon Gomez, Cesar L Messiah, Sarah E Kohl, Harold W Kelder, Steven H Ross, Jessica A Padilla, Lindsay N Silberman, Mark Tuzo, Samantha Lakey, David Shuford, Jennifer A Pont, Stephen J Boerwinkle, Eric Swartz, Michael D |
| description | Abstract
Background
Breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are well documented. The current study estimates breakthrough incidence across pandemic waves, and evaluates predictors of breakthrough and severe breakthrough infections (defined as those requiring hospitalization).
Methods
In total, 89 762 participants underwent longitudinal antibody surveillance. Incidence rates were calculated using total person-days contributed. Bias-corrected and age-adjusted logistic regression determined multivariable predictors of breakthrough and severe breakthrough infection, respectively.
Results
The incidence was 0.45 (95% confidence interval [CI], .38–.50) during pre-Delta, 2.80 (95% CI, 2.25–3.14) during Delta, and 11.2 (95% CI, 8.80–12.95) during Omicron, per 10 000 person-days. Factors associated with elevated odds of breakthrough included Hispanic ethnicity (vs non-Hispanic white, OR = 1.243; 95% CI, 1.073–1.441), larger household size (OR = 1.251 [95% CI, 1.048–1.494] for 3–5 vs 1 and OR = 1.726 [95% CI, 1.317–2.262] for more than 5 vs 1 person), rural versus urban living (OR = 1.383; 95% CI, 1.122–1.704), receiving Pfizer or Johnson & Johnson versus Moderna, and multiple comorbidities. Of the 1700 breakthrough infections, 1665 reported on severity; 112 (6.73%) were severe. Higher body mass index, Hispanic ethnicity, vaccine type, asthma, and hypertension predicted severe breakthroughs.
Conclusions
Breakthrough infection was 4–25 times more common during the Omicron-dominant wave versus earlier waves. Higher burden of severe breakthrough infections was identified in subgroups.
Incidence of breakthrough SARS-CoV-2 infection after primary series vaccination was estimated for Alpha, Delta, and Omicron waves. Breakthrough infections were common; incidence was highest during Omicron. Higher BMI, Hispanic ethnicity, vaccine type, asthma, and hypertension were predictive of severe breakthrough. |
| doi_str_mv | 10.1093/infdis/jiad020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2771943073</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/infdis/jiad020</oup_id><sourcerecordid>3051796059</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-dfb0b3c64809473877c6979dd4768a9d5745a92877c4f898353c0d98fa916e6a3</originalsourceid><addsrcrecordid>eNqFkUtv1DAUhS0EokNhyxJZYgOLtH4kccwuHfEYqRIjBrqNPPYN9ZCxUzuu1D_G78MzGZBgw8aWzv3OsXUPQi8puaBE8kvremPj5c4qQxh5hBa04qKoa8ofowUhjBW0kfIMPYtxRwgpeS2eorN8MkmFWKCfK6etAacBK2fwOoCxevIhYt_jqwDqx3QbfPp-exxv4B4C_K2vXA96st4dLZv2y6ZY-puC4bafIOREu1fhIVuDhYhvlNbWqQOPrcOtScMU3-EWr_2YhqNeXKkI-a0U7uHhkMkYrkSF1ypMVttRuSk-R096NUR4cbrP0bcP778uPxXXnz-ulu11obkUU2H6LdlyXZcNkaXgjRC6lkIaU4q6UdJUoqyUZAe97BvZ8IprYmTTK0lrqBU_R2_m3DH4uwRx6vY2ahgG5cCn2DEhqCw5ETyjr_9Bdz4Fl3_XcVJRIWtSyUxdzJQOPsYAfTfOC-oo6Q6NdnOj3anRbHh1ik3bPZg_-O8KM_B2Bnwa_xf2C_wwrIc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3051796059</pqid></control><display><type>article</type><title>Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>DeSantis, Stacia M ; Yaseen, Ashraf ; Hao, Tianyao ; León-Novelo, Luis ; Talebi, Yashar ; Valerio-Shewmaker, Melissa A ; Pinzon Gomez, Cesar L ; Messiah, Sarah E ; Kohl, Harold W ; Kelder, Steven H ; Ross, Jessica A ; Padilla, Lindsay N ; Silberman, Mark ; Tuzo, Samantha ; Lakey, David ; Shuford, Jennifer A ; Pont, Stephen J ; Boerwinkle, Eric ; Swartz, Michael D</creator><creatorcontrib>DeSantis, Stacia M ; Yaseen, Ashraf ; Hao, Tianyao ; León-Novelo, Luis ; Talebi, Yashar ; Valerio-Shewmaker, Melissa A ; Pinzon Gomez, Cesar L ; Messiah, Sarah E ; Kohl, Harold W ; Kelder, Steven H ; Ross, Jessica A ; Padilla, Lindsay N ; Silberman, Mark ; Tuzo, Samantha ; Lakey, David ; Shuford, Jennifer A ; Pont, Stephen J ; Boerwinkle, Eric ; Swartz, Michael D</creatorcontrib><description>Abstract
Background
Breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are well documented. The current study estimates breakthrough incidence across pandemic waves, and evaluates predictors of breakthrough and severe breakthrough infections (defined as those requiring hospitalization).
Methods
In total, 89 762 participants underwent longitudinal antibody surveillance. Incidence rates were calculated using total person-days contributed. Bias-corrected and age-adjusted logistic regression determined multivariable predictors of breakthrough and severe breakthrough infection, respectively.
Results
The incidence was 0.45 (95% confidence interval [CI], .38–.50) during pre-Delta, 2.80 (95% CI, 2.25–3.14) during Delta, and 11.2 (95% CI, 8.80–12.95) during Omicron, per 10 000 person-days. Factors associated with elevated odds of breakthrough included Hispanic ethnicity (vs non-Hispanic white, OR = 1.243; 95% CI, 1.073–1.441), larger household size (OR = 1.251 [95% CI, 1.048–1.494] for 3–5 vs 1 and OR = 1.726 [95% CI, 1.317–2.262] for more than 5 vs 1 person), rural versus urban living (OR = 1.383; 95% CI, 1.122–1.704), receiving Pfizer or Johnson & Johnson versus Moderna, and multiple comorbidities. Of the 1700 breakthrough infections, 1665 reported on severity; 112 (6.73%) were severe. Higher body mass index, Hispanic ethnicity, vaccine type, asthma, and hypertension predicted severe breakthroughs.
Conclusions
Breakthrough infection was 4–25 times more common during the Omicron-dominant wave versus earlier waves. Higher burden of severe breakthrough infections was identified in subgroups.
Incidence of breakthrough SARS-CoV-2 infection after primary series vaccination was estimated for Alpha, Delta, and Omicron waves. Breakthrough infections were common; incidence was highest during Omicron. Higher BMI, Hispanic ethnicity, vaccine type, asthma, and hypertension were predictive of severe breakthrough.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jiad020</identifier><identifier>PMID: 36729177</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Adult ; Body mass index ; Breakthrough Infections ; Comorbidity ; Coronaviruses ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; Ethnicity ; Humans ; Incidence ; Infections ; Minority & ethnic groups ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Vaccination</subject><ispartof>The Journal of infectious diseases, 2023-05, Vol.227 (10), p.1164-1172</ispartof><rights>Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023. 2023</rights><rights>Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-dfb0b3c64809473877c6979dd4768a9d5745a92877c4f898353c0d98fa916e6a3</citedby><cites>FETCH-LOGICAL-c397t-dfb0b3c64809473877c6979dd4768a9d5745a92877c4f898353c0d98fa916e6a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36729177$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DeSantis, Stacia M</creatorcontrib><creatorcontrib>Yaseen, Ashraf</creatorcontrib><creatorcontrib>Hao, Tianyao</creatorcontrib><creatorcontrib>León-Novelo, Luis</creatorcontrib><creatorcontrib>Talebi, Yashar</creatorcontrib><creatorcontrib>Valerio-Shewmaker, Melissa A</creatorcontrib><creatorcontrib>Pinzon Gomez, Cesar L</creatorcontrib><creatorcontrib>Messiah, Sarah E</creatorcontrib><creatorcontrib>Kohl, Harold W</creatorcontrib><creatorcontrib>Kelder, Steven H</creatorcontrib><creatorcontrib>Ross, Jessica A</creatorcontrib><creatorcontrib>Padilla, Lindsay N</creatorcontrib><creatorcontrib>Silberman, Mark</creatorcontrib><creatorcontrib>Tuzo, Samantha</creatorcontrib><creatorcontrib>Lakey, David</creatorcontrib><creatorcontrib>Shuford, Jennifer A</creatorcontrib><creatorcontrib>Pont, Stephen J</creatorcontrib><creatorcontrib>Boerwinkle, Eric</creatorcontrib><creatorcontrib>Swartz, Michael D</creatorcontrib><title>Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Abstract
Background
Breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are well documented. The current study estimates breakthrough incidence across pandemic waves, and evaluates predictors of breakthrough and severe breakthrough infections (defined as those requiring hospitalization).
Methods
In total, 89 762 participants underwent longitudinal antibody surveillance. Incidence rates were calculated using total person-days contributed. Bias-corrected and age-adjusted logistic regression determined multivariable predictors of breakthrough and severe breakthrough infection, respectively.
Results
The incidence was 0.45 (95% confidence interval [CI], .38–.50) during pre-Delta, 2.80 (95% CI, 2.25–3.14) during Delta, and 11.2 (95% CI, 8.80–12.95) during Omicron, per 10 000 person-days. Factors associated with elevated odds of breakthrough included Hispanic ethnicity (vs non-Hispanic white, OR = 1.243; 95% CI, 1.073–1.441), larger household size (OR = 1.251 [95% CI, 1.048–1.494] for 3–5 vs 1 and OR = 1.726 [95% CI, 1.317–2.262] for more than 5 vs 1 person), rural versus urban living (OR = 1.383; 95% CI, 1.122–1.704), receiving Pfizer or Johnson & Johnson versus Moderna, and multiple comorbidities. Of the 1700 breakthrough infections, 1665 reported on severity; 112 (6.73%) were severe. Higher body mass index, Hispanic ethnicity, vaccine type, asthma, and hypertension predicted severe breakthroughs.
Conclusions
Breakthrough infection was 4–25 times more common during the Omicron-dominant wave versus earlier waves. Higher burden of severe breakthrough infections was identified in subgroups.
Incidence of breakthrough SARS-CoV-2 infection after primary series vaccination was estimated for Alpha, Delta, and Omicron waves. Breakthrough infections were common; incidence was highest during Omicron. Higher BMI, Hispanic ethnicity, vaccine type, asthma, and hypertension were predictive of severe breakthrough.</description><subject>Adult</subject><subject>Body mass index</subject><subject>Breakthrough Infections</subject><subject>Comorbidity</subject><subject>Coronaviruses</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>Ethnicity</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infections</subject><subject>Minority & ethnic groups</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccination</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1DAUhS0EokNhyxJZYgOLtH4kccwuHfEYqRIjBrqNPPYN9ZCxUzuu1D_G78MzGZBgw8aWzv3OsXUPQi8puaBE8kvremPj5c4qQxh5hBa04qKoa8ofowUhjBW0kfIMPYtxRwgpeS2eorN8MkmFWKCfK6etAacBK2fwOoCxevIhYt_jqwDqx3QbfPp-exxv4B4C_K2vXA96st4dLZv2y6ZY-puC4bafIOREu1fhIVuDhYhvlNbWqQOPrcOtScMU3-EWr_2YhqNeXKkI-a0U7uHhkMkYrkSF1ypMVttRuSk-R096NUR4cbrP0bcP778uPxXXnz-ulu11obkUU2H6LdlyXZcNkaXgjRC6lkIaU4q6UdJUoqyUZAe97BvZ8IprYmTTK0lrqBU_R2_m3DH4uwRx6vY2ahgG5cCn2DEhqCw5ETyjr_9Bdz4Fl3_XcVJRIWtSyUxdzJQOPsYAfTfOC-oo6Q6NdnOj3anRbHh1ik3bPZg_-O8KM_B2Bnwa_xf2C_wwrIc</recordid><startdate>20230512</startdate><enddate>20230512</enddate><creator>DeSantis, Stacia M</creator><creator>Yaseen, Ashraf</creator><creator>Hao, Tianyao</creator><creator>León-Novelo, Luis</creator><creator>Talebi, Yashar</creator><creator>Valerio-Shewmaker, Melissa A</creator><creator>Pinzon Gomez, Cesar L</creator><creator>Messiah, Sarah E</creator><creator>Kohl, Harold W</creator><creator>Kelder, Steven H</creator><creator>Ross, Jessica A</creator><creator>Padilla, Lindsay N</creator><creator>Silberman, Mark</creator><creator>Tuzo, Samantha</creator><creator>Lakey, David</creator><creator>Shuford, Jennifer A</creator><creator>Pont, Stephen J</creator><creator>Boerwinkle, Eric</creator><creator>Swartz, Michael D</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20230512</creationdate><title>Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants</title><author>DeSantis, Stacia M ; Yaseen, Ashraf ; Hao, Tianyao ; León-Novelo, Luis ; Talebi, Yashar ; Valerio-Shewmaker, Melissa A ; Pinzon Gomez, Cesar L ; Messiah, Sarah E ; Kohl, Harold W ; Kelder, Steven H ; Ross, Jessica A ; Padilla, Lindsay N ; Silberman, Mark ; Tuzo, Samantha ; Lakey, David ; Shuford, Jennifer A ; Pont, Stephen J ; Boerwinkle, Eric ; Swartz, Michael D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-dfb0b3c64809473877c6979dd4768a9d5745a92877c4f898353c0d98fa916e6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Body mass index</topic><topic>Breakthrough Infections</topic><topic>Comorbidity</topic><topic>Coronaviruses</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>Ethnicity</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infections</topic><topic>Minority & ethnic groups</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DeSantis, Stacia M</creatorcontrib><creatorcontrib>Yaseen, Ashraf</creatorcontrib><creatorcontrib>Hao, Tianyao</creatorcontrib><creatorcontrib>León-Novelo, Luis</creatorcontrib><creatorcontrib>Talebi, Yashar</creatorcontrib><creatorcontrib>Valerio-Shewmaker, Melissa A</creatorcontrib><creatorcontrib>Pinzon Gomez, Cesar L</creatorcontrib><creatorcontrib>Messiah, Sarah E</creatorcontrib><creatorcontrib>Kohl, Harold W</creatorcontrib><creatorcontrib>Kelder, Steven H</creatorcontrib><creatorcontrib>Ross, Jessica A</creatorcontrib><creatorcontrib>Padilla, Lindsay N</creatorcontrib><creatorcontrib>Silberman, Mark</creatorcontrib><creatorcontrib>Tuzo, Samantha</creatorcontrib><creatorcontrib>Lakey, David</creatorcontrib><creatorcontrib>Shuford, Jennifer A</creatorcontrib><creatorcontrib>Pont, Stephen J</creatorcontrib><creatorcontrib>Boerwinkle, Eric</creatorcontrib><creatorcontrib>Swartz, Michael D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DeSantis, Stacia M</au><au>Yaseen, Ashraf</au><au>Hao, Tianyao</au><au>León-Novelo, Luis</au><au>Talebi, Yashar</au><au>Valerio-Shewmaker, Melissa A</au><au>Pinzon Gomez, Cesar L</au><au>Messiah, Sarah E</au><au>Kohl, Harold W</au><au>Kelder, Steven H</au><au>Ross, Jessica A</au><au>Padilla, Lindsay N</au><au>Silberman, Mark</au><au>Tuzo, Samantha</au><au>Lakey, David</au><au>Shuford, Jennifer A</au><au>Pont, Stephen J</au><au>Boerwinkle, Eric</au><au>Swartz, Michael D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2023-05-12</date><risdate>2023</risdate><volume>227</volume><issue>10</issue><spage>1164</spage><epage>1172</epage><pages>1164-1172</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Abstract
Background
Breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are well documented. The current study estimates breakthrough incidence across pandemic waves, and evaluates predictors of breakthrough and severe breakthrough infections (defined as those requiring hospitalization).
Methods
In total, 89 762 participants underwent longitudinal antibody surveillance. Incidence rates were calculated using total person-days contributed. Bias-corrected and age-adjusted logistic regression determined multivariable predictors of breakthrough and severe breakthrough infection, respectively.
Results
The incidence was 0.45 (95% confidence interval [CI], .38–.50) during pre-Delta, 2.80 (95% CI, 2.25–3.14) during Delta, and 11.2 (95% CI, 8.80–12.95) during Omicron, per 10 000 person-days. Factors associated with elevated odds of breakthrough included Hispanic ethnicity (vs non-Hispanic white, OR = 1.243; 95% CI, 1.073–1.441), larger household size (OR = 1.251 [95% CI, 1.048–1.494] for 3–5 vs 1 and OR = 1.726 [95% CI, 1.317–2.262] for more than 5 vs 1 person), rural versus urban living (OR = 1.383; 95% CI, 1.122–1.704), receiving Pfizer or Johnson & Johnson versus Moderna, and multiple comorbidities. Of the 1700 breakthrough infections, 1665 reported on severity; 112 (6.73%) were severe. Higher body mass index, Hispanic ethnicity, vaccine type, asthma, and hypertension predicted severe breakthroughs.
Conclusions
Breakthrough infection was 4–25 times more common during the Omicron-dominant wave versus earlier waves. Higher burden of severe breakthrough infections was identified in subgroups.
Incidence of breakthrough SARS-CoV-2 infection after primary series vaccination was estimated for Alpha, Delta, and Omicron waves. Breakthrough infections were common; incidence was highest during Omicron. Higher BMI, Hispanic ethnicity, vaccine type, asthma, and hypertension were predictive of severe breakthrough.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>36729177</pmid><doi>10.1093/infdis/jiad020</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2023-05, Vol.227 (10), p.1164-1172 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2771943073 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Body mass index Breakthrough Infections Comorbidity Coronaviruses COVID-19 - epidemiology COVID-19 - prevention & control Ethnicity Humans Incidence Infections Minority & ethnic groups SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Vaccination |
| title | Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T03%3A48%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20and%20Predictors%20of%20Breakthrough%20and%20Severe%20Breakthrough%20Infections%20of%20SARS-CoV-2%20After%20Primary%20Series%20Vaccination%20in%20Adults:%20A%20Population-Based%20Survey%20of%2022%20575%20Participants&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=DeSantis,%20Stacia%20M&rft.date=2023-05-12&rft.volume=227&rft.issue=10&rft.spage=1164&rft.epage=1172&rft.pages=1164-1172&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jiad020&rft_dat=%3Cproquest_cross%3E3051796059%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3051796059&rft_id=info:pmid/36729177&rft_oup_id=10.1093/infdis/jiad020&rfr_iscdi=true |